ObjectiveTo investigate the clinical efficacy of glucosamine hydrochloride tablets in treating knee cartilage injury resulting from rheumatoid arthritis. MethodsWe selected 200 knee cartilage injury patients with rheumatoid arthritis treated in our hospital from January 2011 to January 2015 as the research subjects. They were divided into control group (n=98) and observation group (n=102) according to the time of admission. The control group was treated with conventional disease modifying anti-rheumatic drugs (DMARDs), while the observation group was treated with glucosamine hydrochloride tablets on the basis of DMARDs. The treatment effect was evaluated and compared between the two groups of patients 18, 36 and 54 weeks after the treatment. ResultsFifty-four weeks later, knee pain score of the observation group was better than that of the control group, and the difference was statistically significant (P ＜ 0.05) . The observation group had a lower Noyes evaluation level than the control group, and the difference was statistically significant (P ＜ 0.05) . Adverse reaction in the observation group was 3.92% and it was 3.06% in the control group, and the difference between the two groups was not statistically significant (P ＞ 0.05) . ConclusionGlucosamine hydrochloride tablets combined with conventional anti-rheumatic treatment is effective for knee cartilage injury caused by rheumatoid arthritis, which can promote cartilage repair, and it is worthy of clinical application.
ObjectiveTo evaluate the efficacy and safety of glucosamine hydrochloride in the treatment of osteoarthritis. MethodsA total of 150 patients with osteoarthritis treated between April 2014 and April 2015 were randomly divided into control group and trial group with 75 in each. Patients in the trial group accepted oral glucosamine hydrochloride, while those in the control group were given diclofenac sodium. Lequesne index, total effective rate and the incidence of adverse reactions of both groups were calculated before and 2, 4, 6 and 8 weeks after treatment, and 2 weeks after drug withdrawal. ResultsIn both groups, Lequesne index started to decrease after 2 weeks of treatment (P<0.05), and reached the minimum value at treatment week eight (P<0.05). The Lequesne index 2 weeks after drug withdrawal was still obviously lower than that before treatment (P<0.05). There was no significant differences in the total effective rate at treatment week eight (83.1% for the control group and 80.9% for the trial group) or the total effective rate 2 weeks after drug withdrawal (80.0% for the control group and 79.4% for the trial group) between the control group and the trial group (P>0.05). The incidence of adverse reactions of the trial group (6.7%) was significantly lower than that of the control group (21.3%) (P<0.05). ConclusionGlucosamine hydrochloride is effective and safe in the treatment of osteoarthritis, which is suitable for long-term treatment.
目的 通过观察盐酸氨基葡萄糖、依托芬那酯凝胶治疗颞下颌关节紊乱病（TMD）的临床疗效，探寻治疗老年TMD的有效治疗方法。 方法 对2008年7月－2011年12月收治的 35例老年TMD患者，予口服盐酸氨基葡萄糖胶囊750 mg，2次/d，依托芬那酯凝胶5 cm局部外涂，3～4次/d，治疗时间为6周，并对治疗前、后颞下颌关节疼痛程度和活动度进行临床疗效评价。 结果 经治疗，35例患者颞下颌关节疼痛缓解，关节活动度亦明显改善；依据疗效评定标准，治愈10例，显效16例，好转7例，无效2例，总有效率达94.3%；治疗过程中，4例出现轻度胃胀、恶心等不适，2例出现局部皮肤轻度瘙痒现象，无1例中途退出或失访。 结论 盐酸氨基葡萄糖联合依托芬那酯凝胶治疗老年TMD，能缓解关节症状，改善关节活动度，副作用少，值得临床推广运用。
ObjectiveTo evaluate the therapeutic effect of glucosamine hydrochloride combined with Tenghuangjiangu tablets on knee osteoarthritis. MethodsFrom August 2012 to February 2014, 180 patients with knee osteoarthritis were randomly divided into three groups with 60 in each. Patients in group A were treated with glucosamine hydrochloride; patients in group B were treated with Tenghuangjiangu tablets; and patients in group C were treated with the combination of glucosamine hydrochloride and Tenghuangjiangu tablets. After the 12-week treatment, clinical efficacy and safety of the treatment were observed and compared with those before the treatment. ResultsThe twenty-meter walking pain, Western Ontario and McMaster University Osteoarthritis Index (WOMAC), and the joint tenderness in the three groups 12 weeks after the treatment and 4 weeks after withdrawal improved obviously compared with those before the treatment (P<0.05), and the difference between the results of 12 weeks after treatment and 4 weeks after withdrawal was not significant (P>0.05). The improvement in group C was better than both group A and B with significant differences (P<0.05), while the difference between group A and B was not significant (P>0.05). There was no obvious abnormal routine blood and urine test result or damage of liver and lung functions during the treatment in all the three groups. Twelve weeks after treatment, six patients with abdominal ache were found in group A with an incidence of 10.0%; 5 abdominal ache and 2 diarrhea were in group B with a rate of 12.5%; and 4 abdominal ache and 3 diarrhea were in group C with a rate of 12.5%. All the patients completed the treatment. No significant difference in the incidence of adverse reactions was found among the three groups (P>0.05). ConclusionThe therapeutic effect of combined glucosamine hydrochloride and Tenghuangjiangu tablets is obvious on knee osteoarthritis with low incidence of adverse reactions.
目的:研究双醋瑞因联合盐酸氨基葡萄糖和双氯芬酸钠治疗骨性关节炎的可行性及安全性。方法:选取100例骨性关节炎患者,随机分入双醋瑞因组联合双氯芬酸钠组(A组)、盐酸氨基葡萄糖联合双氯芬酸钠组(B组)、单用双氯芬酸钠组(C组)和双醋瑞因组联合双氯芬酸钠和盐酸氨基葡萄糖组(D组)四组中,用药12周后观察治疗前后临床疗效和综合疗效评分。结果:1.四组治疗方案在VAS评分、关节疼痛度评分方面均有良好改善率;2D组治疗方案优于A、B、C三组。结论:双醋瑞因联合盐酸氨基葡萄糖和双氯芬酸钠治疗骨性关节炎是可行、安全、优效的方案。
目的 探讨氨基葡萄糖联合布洛芬治疗髋关节骨关节炎的临床疗效。 方法 2011年9月－2012年1月采用前瞻性随机对照临床试验，将198例轻、中度髋关节骨关节炎患者随机分入试验组及对照组。试验组采用氨基葡萄糖（750 mg， 2次/d口服，疗程1个月）联合布洛芬（0.3 g，2次/d口服，疗程2周），对照组则单用布洛芬（0.3 g，2次/d口服，疗程2周）；分别于服药后0、2、4、8及12周时采用加拿大西安大略和麦克玛斯特大学骨关节炎指数（WOMAC）进行疗效评价。并对恶心、呕吐、皮疹等药物不良反应进行观察。 结果 试验组与对照组WOMAC各项评分从第2周开始较0周明显下降，而两组患者间在0周及2周时WOMAC评分无统计学差异：0周总评分（45.3、45.0分，P=0.225），2周总评分（37.3、37.6分，P=0.329）。但对照组WOMAC各项评分从第4周开始逐渐呈现上升趋势，而试验组到第12周仍呈现持续性下降趋势。总不良反应发生率为7.0%，其中试验组总不良反应发生率为9.5%，但不良反应轻微，未予特殊处理而自行消失。 结论 氨基葡萄糖联合布洛芬可有效缓解早、中期髋关节骨关节炎各项临床症状，疗效确切，不良反应较少，且停药后仍持续表现出治疗效果。而单用布洛芬可短期缓解骨关节炎症，但停药后症状逐渐复现。
ObjectiveTo discuss the efficacy and safety of the joint application of oral glucosamine hydrochloride tablets and knee joint cavity ozone injection in the treatment of knee osteoarthritis. MethodsFrom January 2014 to January 2015, 72 patients who matched the criteria of moderate knee osteoarthritis were randomly divided into two groups according to the table of random number: oral glucosamine hydrochloride tablet and knee joint cavity ozone injection group (group G+O) and ozone group (group O). Patients of group G+O orally took glucosamine hydrochloride tablets (0.48 g, 3 times/day) for twelve weeks, and ozone was injected into the patients’ knee joint once a week for the first four weeks. The treatment for group O patients was the same with Group G+O, except that the glucosamine hydrochloride tablets were replaced by glucosamine hydrochloride placebo (2 tablets, 3 times/day, taking orally). We recorded the Visual Analogue Scale (VAS) score, Western Ontario & McMaster University (WOMAC) osteoarthritis index score and the adverse reactions before treatment and in the first, third and sixth month after treatment. ResultsPatients’ VAS scores and WOMAC scores of both the two groups in the first, third and sixth month after treatment were significantly different from those before the treatment (P ＜ 0.05) . In the first month after treatment, there were no significant difference in patients’ VAS scores and WOMAC scores between the two groups (P ＞ 0.05) . In the third and sixth month after treatment, there were significant differences in patients’ VAS scores and WOMAC scores between the two groups (P ＜ 0.05) . There was no obvious adverse reactions during the treatment. ConclusionsThe combined application of oral glucosamine hydrochloride tablets and knee joint cavity ozone injection and the ozone treatment for moderate knee osteoarthritis are both effective, without any adverse reaction. The combined treatment of oral glucosamine hydrochloride tablets and knee joint cavity ozone injection on moderate knee osteoarthritis has better long-term efficacy, and it is worth spreading.
【摘要】 目的 观察盐酸氨基葡萄糖治疗腰椎关节突关节骨性关节炎（lumbar zygapophyseal joint osteoarthritis，LZOA）的临床疗效及安全性。 方法 2009年1月-2010年1月，对90例LZOA患者随机分成治疗组和对照组，各45例。治疗组口服盐酸氨基葡萄糖，6周为1个疗程，治疗3个疗程，前2周均加用洛索洛芬钠；对照组患者仅给予洛索洛芬钠口服12周。比较两组治疗后2、6周及3、6、12个月的疗效及安全性。 结果 治疗后6周、3个月，治疗组与对照组症状均明显改善，对照组改善更明显。治疗6个月后，治疗组评分持续下降，到12个月时与治疗前比较差异有统计学意义（Plt;0.01）；而对照组评分则逐渐增高，到12个月时与其治疗前比较差异无统计学意义（Pgt;0.05）。两组的不良反应率分别为6.67%、15.56%，差异有统计学意义（Plt;0.01）。 结论 盐酸氨基葡萄糖治疗LZOA疗效确切，且安全性良好。【Abstract】 Objective To observe the clinical efficacy and safety of glucosamine hydrochloride on lumbar zygapophyseal joint osteoarthritis (LZOA). Methods From January 2009 to January 2010, 90 patients with LZOA were randomly divided into therapeutic group and comparative group, with 45 patients in each group. Patients in therapeutic group were treated with oral administration of glucosamine hydrochloride for 3 courses (6 weeks for one course; adding loxoprofen for the early 2 weeks). Patients in comparative group were treated with oral administration of loxoprofen for 12 weeks. The efficacy and safety between the two groups was compared. Results Symptoms in both group were relieved after 6-week and 3-month treatment. More obvious relief was observed in the comparative group. The scoring of therapeutic group kept decreasing after 6-month treatment. The efficacy showed significant improvement after 12-month treatment compared with which before the treatment was significant（Plt;0.01）. The scoring in comparative group kept increasing, which showed no significant difference after 12-month treatment（Pgt;0.05）. The adverse effect rate was 6.67% and 15.56% respectively in two groups, which was significant different（Plt;0.01）. Conclusions Glucosamine hydrochloride provides good efficacy and safety for patients with LZOA.
ObjectiveTo observe and study the clinical effect of glucosamine in the treatment of patients with knee articular cartilage injury caused by rheumatoid arthritis. MethodsForty-six patients with knee articular cartilage injury caused by rheumatoid arthritis treated from January 2013 to June 2015 were selected as the research subjects, and they were randomly divided into control group (conventional treatment group, n=23) and observation group (conventional and glucosamine treatment group, n=23) . Then the Noyes classification and serum articular cartilage injury related indexes [cartilage oligomeric matrix protein (COMP), matrix metalloproteinase (MMP)-1, MMP-3 and mouse tissue inhibitors of metalloproteinase (TIMP)-1], inflammatory indexes [tumor necrosis factor (TNF)-α, interleukin (IL)- 17 and IL-33] of the two groups before and after treatment were compared. ResultsIn the observation group, after treatment for 4, 8 and 12 weeks, Noyes grade was better than that in the control group, but with no statistical significance (P ＞ 0.05) . In the observation group, after treatment for 4, 8 and 12 weeks, serum inflammatory markers serum COMP, MMP-1, MMP-3 and TIMP-1 and other related indicators of cartilage damage and serum TNF-α, IL-17 and IL-33 were all significantly lower than those in the control group (P ＜ 0.05) . ConclusionIn the treatment of patients with knee articular cartilage injury caused by rheumatoid arthritis, glucosamine has active role for the improvement of articular cartilage injury and inflammatory stress state of patients.
ObjectiveTo explore the therapeutic effect of glucosamine hydrochloride combined with calcium and vitamin D on knee osteoarthritis. MethodsA total of 120 female outpatients with knee osteoarthritis from January 2014 to January 2015 were selected. The patients were randomly divided into study group and control group (60 patients in each group) according to their treatment sequence. The patients in the study group were given oral calcium citrate, alfacalcidol and glucosamine hydrochloride while those in the control group were given glucosamine hydrochloride only. Both groups were investigated and scored by Western Ontario and McMaster University Osteoarthritis Index (WOMAC) questionnaire before and three and six months after treatment. ResultsThree and six months after the treatment, WOMAC scores of both groups were lower than those before the treatment with significant differences (P<0.05). Three months after the treatment, WOMAC scores between the two groups didn't differ much (P>0.05), while the difference between the two groups was significant 6 months after the treatment (P<0.05). Three months after the treatment, the difference of total effective rate in the study group (43.3%) and control group (41.7%) was not significant (P>0.05), while the rate in the study group (65.0%) was obviously higher than that in the control group (46.7%) 6 months after the treatment (P<0.05). ConclusionGlucosamine hydrochloride has exact effect on knee osteoarthritis. There are differences in the therapeutic effect on knee osteoarthritis between glucosamine hydrochloride combined with calcium and vitamin D and glucosamine hydrochloride alone after six-month treatment.